T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Wells Fargo
WFC
|
+$1.31B |
| 2 |
Home Depot
HD
|
+$1.07B |
| 3 |
Alibaba
BABA
|
+$1.06B |
| 4 |
Yum! Brands
YUM
|
+$887M |
| 5 |
Honeywell
HON
|
+$860M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
N
Netsuite Inc
N
|
+$1.59B |
| 2 |
NXP Semiconductors
NXPI
|
+$1.33B |
| 3 |
Danaher
DHR
|
+$1.13B |
| 4 |
HBI
Hanesbrands
HBI
|
+$1.06B |
| 5 |
Thermo Fisher Scientific
TMO
|
+$845M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.06% |
| 2 | Financials | 16.98% |
| 3 | Consumer Discretionary | 15.13% |
| 4 | Technology | 13.74% |
| 5 | Industrials | 9.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1326
Theravance Biopharma
TBPH
$880M
| $9.19M | ﹤0.01% |
288,365
-26,958
| -9% | -$836K |
|
1327
NETSCOUT
NTCT
$2.88B
| $9.09M | ﹤0.01% |
288,547
-44,218
| -13% | -$1.36M |
|
1328
Trimble
TRMB
$13.3B
| $9.06M | ﹤0.01% |
300,649
+4,718
| +2% | +$135K |
|
|
ALDR
1329
DELISTED
Alder Biopharmaceuticals
ALDR
| $9.06M | ﹤0.01% |
435,629
+145,183
| +50% | +$3.78M |
|
1330
Under Armour Class C
UA
$2.26B
| $8.93M | ﹤0.01% |
354,681
| – | – |
|
1331
Markel Group
MKL
$22.9B
| $8.89M | ﹤0.01% |
9,833
+1,370
| +16% | +$1.22M |
|
|
TGNA
1332
DELISTED
TEGNA Inc
TGNA
| $8.87M | ﹤0.01% |
647,880
+4,641
| +0.7% | +$63.2K |
|
|
KATE
1333
DELISTED
Kate Spade & Company
KATE
| $8.84M | ﹤0.01% |
473,333
-119,691
| -20% | -$1.96M |
|
1334
Corvus Pharmaceuticals
CRVS
$1.24B
| $8.76M | ﹤0.01% |
612,577
-25,720
| -4% | -$391K |
|
1335
Core Laboratories
CLB
$580M
| $8.75M | ﹤0.01% |
72,900
+100
| +0.1% | +$11.1K |
|
|
HOME
1336
DELISTED
At Home Group Inc.
HOME
| $8.61M | ﹤0.01% |
588,553
-332,731
| -36% | -$4.26M |
|
1337
CorVel
CRVL
$3.3B
| $8.61M | ﹤0.01% |
705,558
-12,000
| -2% | -$137K |
|
1338
Alarm.com
ALRM
$2.73B
| $8.56M | ﹤0.01% |
307,735
+72,723
| +31% | +$2.11M |
|
|
ANSS
1339
DELISTED
Ansys
ANSS
| $8.45M | ﹤0.01% |
91,376
+369
| +0.4% | +$34K |
|
|
HZNP
1340
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $8.45M | ﹤0.01% |
522,220
+13,200
| +3% | +$239K |
|
|
MRUS
1341
DELISTED
Merus
MRUS
| $8.41M | ﹤0.01% |
398,229
-1,671
| -0.4% | -$28.5K |
|
|
CHUBK
1342
DELISTED
CommerceHub, Inc. Series C Common Stock
CHUBK
| $8.31M | ﹤0.01% |
553,260
-1,374,135
| -71% | -$20.6M |
|
1343
Opko Health
OPK
$1.01B
| $8.27M | ﹤0.01% |
888,801
-59,070
| -6% | -$611K |
|
1344
iShares MSCI India ETF
INDA
$6.55B
| $8.23M | ﹤0.01% |
306,900
| – | – |
|
|
CLC
1345
DELISTED
Clarcor
CLC
| $8.21M | ﹤0.01% |
99,590
-1,381,786
| -93% | -$97.5M |
|
1346
Supernus Pharmaceuticals
SUPN
$2.78B
| $7.92M | ﹤0.01% |
313,645
+290,960
| +1,283% | +$6.5M |
|
1347
Gray Television
GTN
$540M
| $7.82M | ﹤0.01% |
721,100
+600
| +0.1% | +$5.89K |
|
1348
Pilgrim's Pride
PPC
$6.6B
| $7.82M | ﹤0.01% |
411,738
+363,082
| +746% | +$7.09M |
|
|
ITCI
1349
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $7.8M | ﹤0.01% |
516,622
-47,080
| -8% | -$665K |
|
1350
Wayfair
W
$14B
| $7.79M | ﹤0.01% |
222,305
-153,901
| -41% | -$5.53M |
|
Similar funds
T. Rowe Price Associates's Q4 2016 Portfolio in Review
As of Q4 2016, T. Rowe Price Associates held 2,620 positions worth $504B, up 1.2% from $498B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q4 2016 filing shows 96 new, 950 increased, 1,023 reduced and 72 closed positions. Its largest new stake was Adient: 10,357,941 shares worth $607M. The largest sale was Netsuite Inc, an estimated $1.59B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 19% a quarter earlier, followed by Financials and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2016 buy was Adient: 10,357,941 shares worth $607M.
- T. Rowe Price Associates added most to Wells Fargo in Q4 2016, an estimated $1.31B increase.
- T. Rowe Price Associates's biggest Q4 2016 reduction was NXP Semiconductors, cutting an estimated $1.33B.
- T. Rowe Price Associates fully exited Netsuite Inc in Q4 2016, selling an estimated $1.59B.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $504B portfolio in Q4 2016.
- T. Rowe Price Associates opened 96 new positions and closed 72 in Q4 2016.
- T. Rowe Price Associates's portfolio value rose 1.2% quarter-over-quarter to $504B.
Based on T. Rowe Price Associates's 13F filing for Q4 2016, filed 14 Feb 2017.